Last update:
Eli Lily costs Maunzaro at a price of about 4,375 ($ 50) for a single 5 mg injection, while the 2.5 mg variant is priced at Rs 3,500 ($ 40.54).
Mounjaro targets GLP-1 and GIP hormones to help weight loss.
In the hope of millions of obesity and diabetes, American multinational pharmaceutical company Elli Lily has started its weight loss drug, silence in India. The drug already creating waves in Europe and the United States has received approval from the Central Drug Standards Control Organization (CDSCO) to sell in the Indian market.
The arrival of Maunjaro occurs at a time when obesity and diabetes face important public health challenges across the country, demanding effective treatment, and the introduction of this drug is being seen as a possible game-chanter.
Eli Lily costs Maunzaro at a price of about 4,375 ($ 50) for a single 5 mg injection, while the 2.5 mg variant is priced at Rs 3,500 ($ 40.54). For people with a regular 5 mg dose, monthly expenditure can exceed Rs 16,000, which can keep the drug out of access to several without adequate insurance coverage.
Despite its high price, the demand for drug is expected to be strengthened in view of the increasing proliferation of obesity related health concerns in the country.
How does Mounjaro work?
Medical experts believe that silence provides a significant benefit on existing weight loss drugs. Dr. According to Manisha Arora, as stated in the Indian Express, the drug mimics two major hormones: glucagon -like peptide -1 (GLP -1) and Gastric Inhibitory Polypeptide (GIP). These hormones play an important role in regulating blood sugar levels, suppressing hunger and slowing down digestion, eventually reduced the feeling of perfection and food intake.
This dual-action mechanism distinguishes mounjaro from other widely used weight loss drugs such as ozmpic, which only targets GLP-1 hormone.
Who can use Mounjaro?
Mounjaro is mainly intended to adults with types of type 2 diabetes and obesity. It is said to be particularly beneficial for people suffering from both conditions simultaneously. However, the drug should only be taken under medical supervision and is not suitable for some groups, including:
- pregnant women
- Patients with type 1 diabetes
- Pilgrim
- With severe gastrointestinal disorders
While the high cost of Maunjaro can limit its access, its potential impact on obesity and diabetes can pave the way for better health results.
